SCHEMBL20239244

SCHEMBL20239244

Cc1nc(CNc2ncc(Cl)cn2)cc(Oc2ccc(CCNC(=O)O)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.48
PLAAT3 P53816 2/20 0.40
PLAAT5 Q96KN8 2/20 0.40
PLAAT2 Q9NWW9 2/20 0.40
PLAAT4 Q9UL19 2/20 0.40
CYP3A4 P08684 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 2/20 0.39
LTA4H P09960 1/20 0.39
ACACB O00763 1/20 0.39
OPRM1 P35372 6/20 0.38
OPRD1 P41143 6/20 0.38
OPRK1 P41145 4/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20259192 0.93 DGAT2 (0.47) DGAT2PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL20239232 0.92 DGAT2 (0.46) DGAT2PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL20239192 0.90 OPRM1 (0.40) DGAT2PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL20239165 0.90 DGAT2 (0.47) DGAT2PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL20259119 0.89 DGAT2 (0.44) DGAT2PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL20239282 0.86 MAP2K7 (0.44) DGAT2PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL18249813 0.85 DGAT2 (0.51) DGAT2CYP3A4ALDH1A1VNN1NPC1
SCHEMBL20239307 0.85 DGAT2 (0.55) DGAT2CYP3A4ALDH1A1HDAC3HDAC1
SCHEMBL20239180 0.84 DGAT2 (0.50) DGAT2CYP3A4OPRM1OPRD1ALDH1A1
SCHEMBL20239234 0.84 DGAT2 (0.46) DGAT2CYP3A4ACACBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885PLAAT3 56/4885PLAAT5 86/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885PLAAT3 67/4885PLAAT5 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.